Advanced search×

Antihyperalgesic effects of (R,E)-N-(2-hydroxy-2,3-dihydro-1H-inden-4-yl)-3-(2-(piperidin-1-yl)-4-(trifluoromethyl)phenyl)-acrylamide (AMG8562), a novel transient receptor potential vanilloid type 1 modulator that does not cause hyperthermia in rats.

Sonya G SG Lehto, Rami R Tamir, Hong H Deng, Lana L Klionsky, Rongzhen R Kuang, April A Le, Doo D Lee, Jean-Claude JC Louis, Ella E Magal, Barton H BH Manning, John J Rubino, Sekhar S Surapaneni, Nuria N Tamayo, Tingrong T Wang, Judy J Wang, Jue J Wang, Weiya W Wang, Brad B Youngblood, Maosheng M Zhang, Dawn D Zhu, Mark H MH Norman, and Narender R NR Gavva

J Pharmacol Exp Ther 326(1):218-29 (2008) PMID 18420600

Antagonists of the vanilloid receptor TRPV1 (transient receptor potential vanilloid type 1) have been reported to produce antihyperalgesic effects in animal models of pain. These antagonists, however, also caused concomitant hyperthermia in rodents, dogs, monkeys, and humans. Antagonist-induced hyperthermia was not observed in TRPV1 knockout mice, suggesting that the hyperthermic effect is exclusively mediated through TRPV1. Since antagonist-induced hyperthermia is considered a hurdle for developing TRPV1 antagonists as therapeutics, we investigated the possibility of eliminating hyperthermia while maintaining antihyperalgesia. Here, we report four potent and selective TRPV1 modulators with unique in vitro pharmacology profiles (profiles A through D) and their respective effects on body temperature. We found that profile C modulator, (R,E)-N-(2-hydroxy-2,3-dihydro-1H-inden-4-yl)-3-(2-(piperidin-1-yl)-4-(trifluoromethyl)phenyl)acrylamide (AMG8562), blocks capsaicin activation of TRPV1, does not affect heat activation of TRPV1, potentiates pH 5 activation of TRPV1 in vitro, and does not cause hyperthermia in vivo in rats. We further profiled AMG8562 in an on-target (agonist) challenge model, rodent pain models, and tested for its side effects. We show that AMG8562 significantly blocks capsaicin-induced flinching behavior, produces statistically significant efficacy in complete Freund's adjuvant- and skin incision-induced thermal hyperalgesia, and acetic acid-induced writhing models, with no profound effects on locomotor activity. Based on the data shown here, we conclude that it is feasible to modulate TRPV1 in a manner that does not cause hyperthermia while maintaining efficacy in rodent pain models.

Referenced by 1 articles

DOI: 10.1124/jpet.107.132233
Version: za2963e q8za5 q8zbb q8zc8 q8zd3 q8ze4 q8zfe q8zgb

Similar articles you may find interesting…

  1. A review of current animal models of osteoarthritis pain.
    Warren N WN D'Souza, Gordon Y GY Ng, ... Sonya G SG Lehto

    Curr Pharm Biotechnol 12(10):1596-612 (2011) PMID 21466452

    Osteoarthritis (OA) is a complex disease plagued by a significant unmet need for treatment. To date, no disease-modifying OA drugs (DMOADs) exist and the available symptom-modifying OA drugs (SMOADs) have limitations. Although a complete understanding of the mechanisms of OA pain in...
  2. Reversal of acid-induced and inflammatory pain by the selective ASIC3 inhibitor, APETx2.
    Jerzy J Karczewski, Robert H RH Spencer, ... Mark O MO Urban

    Br J Pharmacol 161(4):950-60 (2010) PMID 20860671 PMCID PMC2992907

    We studied the in vivo efficacy of a selective ASIC3 inhibitor, APETx2, in rats. KEY RESULTS Administration of APETx2 into the gastrocnemius muscle prior to the administration of low pH saline prevented the development of mechanical hypersensitivity, whereas APETx2 administration following low-pH sa...
    View PDF
  3. DLC-1 operates as a tumor suppressor gene in human non-small cell lung carcinomas.
    Bao-Zhu BZ Yuan, Amy M AM Jefferson, ... Steven H SH Reynolds

    Oncogene 23(7):1405-11 (2004) PMID 14661059

    We examined alterations of DLC-1 in a series of primary tumors and tumor cell lines and tested effects of DLC-1 on tumor cell growth. A significant decrease or absence of the DLC-1 mRNA expression was found in 95% of primary NSCLC (20/21) and 58% of NSCLC cell lines (11/19). Transcriptional silencin...